Clinical Trial Update: Effectiveness Study of the Guardian RT in Type 1 Diabetics [Phase 4]

View source ↗

Summary

Phase 4 post-market effectiveness study evaluating the Guardian RT system in individuals with Type 1 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Guardian RT

Snippet

Sponsor: Medtronic MiniMed, Inc. | Conditions: Type 1 Diabetes Mellitus | Phase 4 | Status: COMPLETED